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Abstract
Classical homeopathy is based on the therapeutic application of highly diluted homeopathic stocks. The indications of such
medicines are determined by proving, i.e. by applying the remedies in healthy subjects. However, there are several complex
homeopathic medicinal products on the market with approved therapeutic indications. The efficacy of these medicines has
been assessed in clinical trials on patients. There is no upper limit of dosing for such homeopathic remedies, and these
products often contain undiluted mother tincture. The aim of our study was to compare an allopathic herbal medicine and a
homeopathic product containing undiluted mother tincture based on the same plant. Two products (an allopathic herbal
medicine and a homeopathic product) containing Vitex agnus-castus extract were analyzed by HPLC-DAD for their agnuside
and casticin contents. The agnuside content of the allopathic product was approximately four times higher, while the
amount of casticin was in the same order of magnitude. Our experiments revealed the presence of active ingredients in
allopathic quantity in a homeopathic preparation, highlighting the controversy between the principles of classical and
practice of contemporary homeopathy. According to the principles of classical homeopathy these remedies cannot be
considered as homeopathic remedies but rather as (allopathic) herbal ones. This phenomenon necessitates a case-by-case
approach towards the possible adverse effects and drug interactions of homeopathics in the daily medical practice.
Homeopathic products containing active agents in allopathic doses should be treated the same way as allopathic medicines
from the point of view of quality assurance and pharmacovigilance.
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Introduction
Homeopathy, an alternative medicinal method developed by
Samuel Hahnemann in the 19th century, is based on the Law of
Similars. According to this, an appropriate homeopathic medicine
contains a reduced dose of a substance which causes symptoms in
a healthy person when administered in a larger quantity. The
homeopathic medicinal product stimulates the self-healing mech-
anisms and the body’s defense system against such symptoms.
Hahnemann was beginning to use ever decreasing amounts of
his preparations, and believed in the power of ‘simplexes’ or
individual medicines, rather than of complex mixtures. Although
classical homeopaths still adhere to Hahnemann’s principles in
prescribing only single remedies, it has been described by some
therapists that certain homeopathic remedies can be mixed and
administered successfully as a complex. Homeopathic complexes
are extremely popular in many countries: in the USA, almost 90%
of all health food outlets keep them. In Europe, several hundreds
of complex homeopathic medicines are on the market. Complex
remedies have never been subjected to provings (i.e. determination
of the curative power of the homeopathic product), although their
constituents may have been proven individually. Therefore
complex remedies cannot be administered according to the Law
of Similars [1].
In European legislation the same directive covers both the
classical individual and complex medicines. According to the
Directive 2001/83/EC, homeopathic medicinal products are
medicinal products prepared from substances called homeopathic
stocks (mother tinctures) in accordance with homeopathic
manufacturing procedures. The Directive distinguishes two major
groups of homeopathic medicines: medicinal products with or
without specific therapeutic indications. Those without specific
therapeutic indications may be subject to a simplified registration
procedure, without the need for confirmation of efficacy. The
registration procedure of homeopathic medicines with therapeutic
indications is the same as that of allopathic medicinal products, i.e.
their safety and efficacy should be proved. Homeopathic remedies
undergoing a simplified registration procedure may not contain
either more than one part per 10 000 of the mother tincture or
more than 1/100th of the smallest dose used in allopathy with
regard to active substances whose presence in an allopathic
medicinal product results in the obligation to submit a doctor’s
prescription. However, for homeopathic remedies with specific
therapeutic indications there is no upper limit of dosing [2].
In Europe, the majority of complex homeopathic medicines are
registered with approved therapeutic indications. About 65% of all
remedies are prepared from extracts of plant materials [1]. Several
complex remedies contain herbal extracts of D1–D4 potencies (i.e.
a 1 in 10 dilution carried out serially 1–4 times) or even the
undiluted mother tincture.
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e74181
Though the analytical assessment of homeopathic preparations
is a novel approach, modern analytical methods allow the
qualitative and quantitative assessment of highly diluted homeo-
pathic products [3,4]. The aim of the present work was to carry
out a qualitative and a quantitative comparative analysis of a herb-
based homeopathic medicine and an authorized medicine based
on the same medicinal plant as a reference. For this purpose, the
homeopathic medicine Mastodynon tablets and the allopathic
medicine Agnucaston coated tablets (both are products of
Bionorica AG, Germany) both containing Vitex agnus-castus L.
(chaste tree) fruit extract were analyzed. Both products have been
approved in several European countries. Two tablets of Masto-
dynon (daily dosage) contain the dry matter of 324 mg Vitex agnus
castus mother tincture, 162 mg Caulophyllum thalictroides D4, 162 mg
Cyclamen europaeum D4, 162 mg Strychnos ignatii D6, 324 mg Iris
versicolor D2, 162 mg Lilium lancifolium D3 [5]. The daily dose of
Agnucaston contains 3.2–4.8 mg Agni casti fructus extract (drug-
extract ratio 8.3–12.51:1, extracting solvent 70% (V/V) ethanol)
[6]. From a materialistic point of view, the main constituent of
both medicines is chasteberry. The mother tincture of Vitex agnus-
castus is produced by maceration or percolation from 1 part freshly
powdered dried ripe fruits and 10 parts 62% m/m (67.4% V/V)
alcohol [7]. Thus, the daily dose of the homeopathic medicine
contains chasteberry extract equivalent to 32.4 mg plant material,
which is similar to that of the allopathic product (43.3 mg), and the
polarity of the extracting solvent applied in case of the latter is also
very similar (70% V/V alcohol).
The indications of the two products are similar (premenstrual
symptoms and irregular menstrual cycle for Mastodynon; [5]
menstrual disturbances, mastodynia and premenstrual syndrome
(PMS) for Agnucaston [6]), which is not usual for allopathic and
homeopathic medicines containing the extract of the same plant.
However, the listed indications are in line with the clinical
evidence for chasteberry. The efficacy of Vitex in PMS is
extensively investigated. In a prospective, randomized, placebo-
controlled study with 178 participants a 60% ethanol extract of
chasteberry corresponding to 180 mg dry plant material per day
on average reduced the symptoms of PMS by the end of the third
menstrual cycle compared to placebo [8]. In an observational
study, 428 women with PMS were treated with a Vitex extract
(solvent 60% ethanol) corresponding to 360 mg plant material.
After three months, 63.3% of the physicians claimed that the three
typical symptoms of PMS from which their female patients
suffered the most were treated successfully [9]. The efficacy of Vitex
has been demonstrated even in a much lower posology. In a
randomized, prospective, double-blind, placebo-controlled, paral-
lel-group, multicenter study with 217 participants, patients
received 4 mg of dried 70% ethanolic extract of chasteberry
(corresponding to 40 mg of plant material) once daily or placebo
throughout three cycles. The symptoms of premenstrual syndrome
decreased significantly in the actively treated group compared to
placebo [10].
The efficacy of homeopathic chasteberry products in PMS has
also been confirmed. In a double-placebo study with 104
participants Mastodynon tablets and solution were assessed for
their effectiveness in relieving mastalgia. At the end of three
menstrual cycles, the intensity of breast pain was significantly
lower for both pharmaceutical forms compared to placebo [11]. In
a double-blind study with 97 participants the intensity of mastalgia
was reduced significantly in the group treated with Mastodynon
solution compared to placebo after three menstrual cycles [12].
The main and characteristic constituents of chasteberry are
flavonoids, compounds of essential oil and diterpenes. Experi-
mental data cites the iridoid glycoside agnuside and the flavonol
casticin as the two quality control markers for pharmaceutical
grade manufacturing [13].
The exact mechanism of action and the active constituents of
Vitex are unknown, however, some of its effects demonstrated
in vitro and in vivo may play a role in the clinical efficacy.
Premenstrual symptoms, particularly mastodynia, are often
accompanied by latent hyperprolactinemia [14]. Mild D2-recep-
tor-agonistic properties of Vitex agnus-castus have been demonstrat-
ed, resulting in suppressed prolactin release from cultivated
lactotrophs as well as in animal experiments. In line with this
observation, serum prolactin levels were indeed reduced in
patients treated with this extract [15]. An agonistic action on m-
and potentially k-opioid receptors may also be of relevance to the
use of Vitex for menopause-related symptoms such as hot flushes
and mood symptoms [14]. Extracts were demonstrated to displace
ligands from human opioid receptor binding [13]. A relatively
potent binding inhibition was observed for opioid receptors (m and
k subtypes) with IC50 values of the native extract between 20 and
70 mg/ml [16]. The results of an in vitro study suggested that Vitex
acts as an agonist at the m-opioid receptor, supporting its beneficial
action in PMS [17]. A 90% methanol extract of chasteberry was
found to bind to and activate m- and d-, but not k-opioid receptor
subtypes. Several flavonoids isolated from Vitex were found to bind
to both m- and d-opioid receptors in a dose-dependent manner;
however only casticin was found to have an agonistic activity
selective for d receptors at high concentrations [18].
Results
In the course of our experiments we quantified the agnuside and
casticin contents of Mastodynon tablets and Agnucaston coated
tablets by HPLC–DAD (Figure 1). The fingerprint chromato-
grams of the two products were very similar. One of the main
differences was that the agnuside/casticin ratio was found to be
2.35 for Agnucaston and 0.54 for Mastodynon. The average
agnuside content of the daily dose of Agnucaston and Mastodynon
was 100.82 mg and 25.19 mg, respectively. The casticin content in
the daily dosage of the two products was 42.95 mg and 47.03 mg,
respectively.
Calibration Curve and Linearity
Linear calibration curves were established in the range of 0,05–
1 mg/injection for agnuside and 0,058–0,58 mg/injection for
casticin. The regression equation for agnuside was y = 1 944
361,72x+27 039,23. The correlation coefficient (R2) was 0.9994.
In case of casticin the regression equation was y = 1 916
347,45x+815,49 (R2 = 0.9996).
Precision
The analytical method is characterized by good precision
(RSD% for agnuside standard solution: 2.41, for casticin: 1.26). In
case of the two products the repeatability of agnuside and casticin
content determination ranges from 2.11 to 5.11 RSD. The
maximal deviation from the average content of casticin and
agnuside was between 92.16% and 109.48%, which complies with
the test for uniformity of content of single-dose preparations of the
European Pharmacopoeia (85%–115%).
Limit of Detection (LOD) and Limit Of Quantitation (LOQ)
The limit of detection obtained for agnuside was 3.872 ng/
injection and limit of quantitation was 12.905 ng/injection. For
casticin, the same values were 1.079 ng/injection and 3.596 ng/
injection, respectively.
Allopathic Homeopathy?
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Peak Purity
Peak purity analysis carried out with the Empower Pro software
confirmed that the chromatographic peaks of agnuside and
casticin were spectrally pure based on the fact that the plot of
purity angles were below the plot of threshold angles and the good
accordance of the UV spectra obtained at three different retention
times (at the peak maximum and +/21/3 of the peak width).
Pearson’s correlation coefficients, characterizing peak purities,
were determined based on the similarities of UV spectra of the
standard solutions and the peaks in the samples in the course of
HPLC-DAD analysis. The correlation coefficients, which were
calculated using spectra detected at the apex, the upslope and the
download segments of the peaks, were higher than 0.998 in all
cases.
Discussion
Based on the chromatographic profile it is hard to distinguish
between the allopathic and the homeopathic medicinal product.
However, it is clear that the two products contain somewhat
different chasteberry extracts since the agnuside/casticin ratios are
different. The quantities of agnuside are of the same order and the
amounts of casticin are practically equal in the daily doses.
Though the two quantified constituents are not necessarily the
active agents of Vitex agnus-castus, these compounds are recognized
as quality control markers and provide information on the
quantity of the herbal extract. The minor constituents of the
homeopathic medicine were not analyzed. However, from an
analytical point of view, Mastodynon is a monocomponent
product when analyzed with HPLC-DAD, since other constituents
are present at concentrations lower by several orders of
magnitude.
Materials and Methods
Mastodynon tablets (lot no. 0000015632) and Agnucaston
coated tablets (lot no. 0000023527) (both produced by Bionorica
AG, Germany) were purchased in a pharmacy in Szeged,
Hungary. Agnuside (99.12% purity) was obtained from Phytolab.
Casticin was isolated from plant material in the Department of
Pharmacognosy, University of Szeged [19]. HPLC grade meth-
anol (LiChrosolvH) was obtained from Merck and phosphoric acid
(85%) from Reanal Fine Chemicals. A Millipore Direct Q-3 water
purification system was used to produce HPLC grade deionized
water.
Preparation of the Extracts
The daily doses of the two products (1 tablet of Agnucaston, 2
tablets of Mastodynon) were sonicated for 15 min in 3 ml
methanol. After 5 min centrifugation at 7500 rpm, the superna-
tant was filtered through an AcrodiscH GHP 13 mm, 0.45 mm
filter (Waters). The first K ml was disposed and the remaining
solution was analyzed by HPLC. From agnuside and casticin,
stock solutions were prepared with methanol (0.05 and 0.029 mg/
ml, respectively).
HPLC Analysis
Extracts of the two chasteberry-containing products were
characterized by HPLC (Waters 600, equipped with a 2998
photodiode array detector, on-line degasser and autosampler)
using a slightly modified fingerprinting method described previ-
ously [16,18]. Using a reversed phase Gemini C18 110 A˚ 1006
4.6 mm 5 mm column (Phenomenex), chromatographic elution
was accomplished by a gradient solvent system consisting of
methanol (A) and 0.5% phosphoric acid in water (B). The gradient
Figure 1. HPLC profiles of the allopathic medicine Agnucaston and the homeopathic preparation Mastodynon (blue: Agnucaston,
black: Mastodynon; agnuside (A), casticin (C)).
doi:10.1371/journal.pone.0074181.g001
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conditions were: 0 min, 5:95 (v:v); 15 min, 27:73; 20 min, 35:65;
26 min, 52:48; 33 min, 80:20; 37 min, 100:0; 45 min 100:0;
50 min, 5:95; 60 min, 5:95. The flow rate was 1.3 ml/min, the
injection volume was 20 ml. Agnuside and casticin were detected at
254 nm and identified based on their retention times and PDA
chromatograms.
Method Validation
From both products, three individual extracts were prepared
and analysed.
Calibration Curve and Linearity
The calibration curve was determined on each day of the
validation; the slope, intercept and the correlation coefficient were
determined. Calibration curves were established within a range of
0.005–0.05 mg/ml for agnuside and 0.0029–0.029 mg/ml for
casticin by diluting the stock solutions with MeOH in appropriate
quantities. The linearities of the calibration curves were assessed
based on 5 points.
Precision
To determine the precision of the analytical method, the same
standard solutions and extracts were subjected to HPLC–DAD
analysis 3 times on the same day. Agnuside and casticin contents of
the samples were measured, and the relative standard deviation
(RSD) values within the measurements were used to evaluate
precision.
Limit Of Detection (LOD) and Limit Of Quantitation (LOQ)
Limit of detection and limit of quantitation were calculated
using the formulas (1) and (2), respectively:
LOD~
3s
S
ð1Þ
LOQ~
10s
S
ð2Þ
where S is the slope of the calibration curve and s~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
S(Y{Yi)
2
n{2
s
where Y is the measured peak area, Yi is the peak area calculated
by the calibration curve, and n is the number of the calibration
points.
Peak Purity
Peak purity analysis was carried out with the Empower Pro
software.
Conclusions
As highlighted by our experiments, homeopathy is not a
uniform medicinal system, and homeopathic remedies can be
grouped into at least two major classes: remedies of high potency
(extremely high dilution and low dose) and those of low potency or
even mother tinctures (doses near or equal to allopathic doses). In
case of the latter group, the principles of Hahnemann are not
applicable. Low dilutions and mother tinctures play a role in
homeopathic prescribing, and are particularly prominent in
systems of homeopathy focusing on the organotropic effects of
homeopathic medicinal products [20]. In the European Union,
the Directive 2001/83/EC [2] allows the authorization of
homeopathic medicines containing allopathic doses, thus the
distinction between low potency homeopathic medications and
allopathic herbal medicines may be based on the intention of the
manufacturer, i.e. on the production method and the rationale
behinds their application and not on the dose. Our results reassure
and highlight that homeopathic products may contain ingredients
in allopathic doses. According to the principles of classical
homeopathy these remedies cannot be considered as homeopathic
remedies but rather as (allopathic) herbal ones. It is arguable
whether products containing herbal extracts with pharmacologi-
cally relevant doses meet the health professionals’ and patients’
expectations for homeopathy. Since these preparations should be
treated the same way as allopathic medicines from the point of
view of pharmacovigilance, health professionals should be aware
of this very special subgroup of homeopathics.
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